前立腺癌に対するEstramustine phosphate disodium(Estracyt)内服療法の臨床的検討

Abstract

Estramustine phosphate disodium (Estracyt) was used in the treatment of 21 patients with prostatic carcinoma in stage B, C and D. Sixteen patients were treated from the onset (primary treatment group) and 5 had previously received some other antiandrogenic therapy (secondary treatment group). The drug was given orally in a dose of 560-840 mg/day for 3 months, if tolerable. The clinical evaluation was done after 3 months' treatment. Recently it was reported that mortality from cardiovascular complications of patients with prostatic cancer was greatest among those patients treated with estrogens. Therefore we studied also about the changes of serum cholesterol and triglyceride levels in the patients undergoing treatment of Estracyt in this report. The results were as follows: 1) The remission of urination difficulties was observed in 78.6% of the primary treatrIlent group and in 40.0% of the secondary treatment group. 2) The significant or moderate reduction of tumor of the prostate was shown in 85.7% of the primary group and in 80.0% of the secondary group. 3) Elevated levels of serum acid phosphatase (total and prostatic) were decreased significantly in the both groups. 4) Over-all clinical effect judged from the subjective and objective remissions was noted in 68.8% of the primary treatment group and in 40.0% of the secondary treatment group. 5) Serum cholesterol levels decreased moderately, on the other hand, marked elevation of serum triglyceride levels was observed in the 2nd months during the treatment with Estracyt. 6) As for the general side-effects, gastrointestinal disorder was shown in 4 patients, and in one of them we had to discontinue this medication. Elevation of serum GOT and GPT levels was transiently observed in 2 cases. Leukopenia was not observed. From these results, we considered that the clinical effect of Estracyt for the patients with prostatic carcinoma was very evaluable. Therapeutic effect can be expected even in the patients who had no response to the previous treatment with some other antiandrogenic agents. The significant elevation of the serum triglyceride levels during the treatment suggests us to take care of cardiovascular complication during long term treatment with Estracyt.